Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 1,004.4% in November

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 100,500 shares, a growth of 1,004.4% from the October 31st total of 9,100 shares. Based on an average daily trading volume, of 320,400 shares, the short-interest ratio is presently 0.3 days.

Astellas Pharma Stock Performance

ALPMY opened at $10.29 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.72 and a current ratio of 0.90. The company has a market cap of $18.62 billion, a PE ratio of 49.00 and a beta of 0.36. The stock has a 50-day moving average of $11.34 and a 200-day moving average of $10.97. Astellas Pharma has a 52-week low of $9.15 and a 52-week high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY) last announced its earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share (EPS) for the quarter. Astellas Pharma had a return on equity of 10.33% and a net margin of 3.26%. The firm had revenue of $3.11 billion during the quarter. As a group, equities research analysts forecast that Astellas Pharma will post 0.61 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.